Abstract:Abstract Background Significant advances in the molecular profiling of gliomas, led the 2016 World Health Organization (WHO) Classification to include, for the first-time, molecular biomarkers in glioma diagnosis: IDH mutations and 1p/19q codeletion. Here, we evaluated the effect of this new classification in the stratification of gliomas previously diagnosed according to 2007 WHO classification. Then, we also analyzed the impact of TERT promoter mutations, PTEN deletion, EGFR amplification and MGMT promoter methylation in diagnosis, prognosis and response to therapy in glioma molecular subgroup. Methods A cohort of 444 adult gliomas was analyzed and reclassified according to the 2016 WHO. Mutational analysis of IDH1 and TERT promoter mutations was performed by Sanger sequencing. Statistical analysis was done using SPSS Statistics 21.0. Results The reclassification of this cohort using 2016 WHO criteria led to a decrease of the number of oligodendrogliomas (from 82 to 49) and an increase of astrocytomas (from 49 to 98), while glioblastomas (GBM) remained the same ( n = 256). GBM was the most common diagnosis (57.7%), of which 55.2% were IDH- wildtype. 1p/19q codeleted gliomas were the subgroup associated with longer median overall survival (198 months), while GBM IDH- wildtype had the worst outcome (10 months). Interestingly, PTEN deletion had poor prognostic value in astrocytomas IDH- wildtype ( p = 0.015), while in GBM IDH- wildtype was associated with better overall survival ( p = 0.042) as well as MGMT promoter methylation ( p = 0.009). EGFR amplification and TERT mutations had no impact in prognosis. Notably, EGFR amplification predicted a better response to radiotherapy ( p = 0.011) and MGMT methylation to chemo-radiotherapy ( p = 0.003). Conclusion In this study we observed that the 2016 WHO classification improved the accuracy of diagnosis and prognosis of diffuse gliomas, although the available biomarkers are not enough. Therefore, we suggest MGMT promoter methylation should be added to glioma classification. Moreover, we found two genetic/clinical correlations that must be evaluated to understand their impact in the clinical setting: i) how is PTEN deletion a favorable prognostic factor in GBM IDH wildtype and an unfavorable prognostic factor in astrocytoma IDH wildtype and ii) how EGFR amplification is an independent and strong factor of response to radiotherapy.

Molecular pathology and clinical implications of diffuse glioma

A contemporary molecular view of diffuse gliomas with implications for diagnosis

Understanding the molecular profiling of diffuse gliomas classification: A brief overview

Clinical importance of molecular markers of adult diffuse glioma

[Advance of Molecular Subtyping and Precise Treatment for Gliomas].

Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification

The Immunohistochemical Expression of IDH1, ATRX, PHH3, P53, Ki67 and Molecular Status of IDH, 1p19q, MGMTp, TERTp in Gliomas: an Analysis of 568 Patients in a Single Center

Latest Developments in Magnetic Resonance Imaging for Evaluating the Molecular Microenvironment of Gliomas

Opinion & Special Article: Glioma Classification

Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors

Glioma Subclassifications and Their Clinical Significance

Glioma targeted therapy: insight into future of molecular approaches

The Molecular Classification of Adult Diffuse Glioma:A Review

Progress in the Application of Molecular Biomarkers in Gliomas

Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma

-New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates

Genetic and molecular epidemiology of adult diffuse glioma

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021

Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma